A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90-Yttrium- Zevalin and the Redox- Modulating Agent, Motexafin Gadolinium (MGd)

Study start date: October 28, 2003

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of one of the following: * Low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) * The following histologies are eligible: * Small lymphocytic lymphoma * Lymphoplasmacytoid lymphoma * Follicular center grades 1, 2, or 3 lymphoma * Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type * Nodal marginal zone B-cell lymphoma * Relapsed or refractory after 2 prior treatment regimens or 1 anthracycline regimen * Diffuse large B-cell NHL or mantle cell lymphoma in first or second relapse * Transformed NHL, defined as low-grade NHL transformed to diffuse large B-cell lymphoma, with no more than 1 relapse since transformation Age 18 and over Recovered from prior immunotherapy Life expectancy At least 3 months Recovered from prior chemotherapy * More than 4 weeks since prior major surgery and recovered * More than 4 weeks since prior anticancer therapy recovered from prior radiotherapy Exclusion criteria: No major bleeding within the past 4 weeks No uncontrolled hypertension No stroke within the past 4 weeks * No active infection * No other active nonmalignant disease * No known G6PD deficiency * No history of porphyria * No other condition that would preclude study participation * No human anti-mouse antibodies * No known history of HIV * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior radioimmunoconjugate therapy * No prior exposure to murine antibodies other than rituximab * More than 4 weeks since prior rituximab * No history of failed stem cell collection